Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1990-2-13
|
| pubmed:abstractText |
Experimental study using nude mice human hepatocellular carcinoma (HCC) xenograft indicated that the combination treatment with iodine 131 (131I)-anti-human HCC isoferritin (131I-isoFtAb), cisplatin, and mixed bacterial vaccine (MBV) yielded better inhibition rate as compared with double combination or 131I-isoFtAb alone. Based on these findings, 25 patients with surgically proven nonresectable and pathologically proven HCC have been treated by radioimmunotherapy using 131I-isoFtAb intrahepatic arterial infusion as a part of multimodality treatment. Of the 25 patients, seven (28.0%) received second-look resection after marked shrinkage of tumor. The 1-year survival was 52.5% (12/23) and 2-year survival 27.7% (five of 18) in the entire series. Of the five patients with 2-year survival, four were in the second-look resection group. Patients with tumor less than or equal to 8 cm showed higher second-look resection rate (62.5% versus 11.8%) and 1-year survival (85.7% versus 37.5%) as compared with tumor greater than 8 cm. Mixed bacterial vaccine as adjuvant immunotherapy seemed effective to prolong survival. The 2-year survival was higher in patients with second-look resection as compared with those without (75.0% versus 14.3%). Thus, radioimmunotherapy using 131I-isoFtAb might be one of the modalities of choice, particularly in the conversion of nonresectable to resectable HCC in a well-designed multimodality treatment regimen.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Bacterial Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Ferritins,
http://linkedlifedata.com/resource/pubmed/chemical/Iodine Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/alpha-Fetoproteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0008-543X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
65
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
211-5
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1688507-Animals,
pubmed-meshheading:1688507-Antibodies,
pubmed-meshheading:1688507-Bacterial Vaccines,
pubmed-meshheading:1688507-Carcinoma, Hepatocellular,
pubmed-meshheading:1688507-Cisplatin,
pubmed-meshheading:1688507-Combined Modality Therapy,
pubmed-meshheading:1688507-Ferritins,
pubmed-meshheading:1688507-Humans,
pubmed-meshheading:1688507-Immunotherapy,
pubmed-meshheading:1688507-Iodine Radioisotopes,
pubmed-meshheading:1688507-Liver Neoplasms,
pubmed-meshheading:1688507-Mice,
pubmed-meshheading:1688507-Mice, Nude,
pubmed-meshheading:1688507-Reoperation,
pubmed-meshheading:1688507-Survival Analysis,
pubmed-meshheading:1688507-alpha-Fetoproteins
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second-look resection.
|
| pubmed:affiliation |
Liver Cancer Institute, Shanghai Medical University, People's Republic of China.
|
| pubmed:publicationType |
Journal Article
|